VCEL.NASDAQVericel CORP

Form 4: Vericel Corp COO Michael Halpin Reports Stock Option and Restricted Stock Unit Grant

Sentiment:

SEC Form 4 Filing


Michael Halpin, Chief Operating Officer of Vericel Corp, reports the acquisition of stock options and restricted stock units.

Summary

  • On February 20, 2025, Michael Halpin, the Chief Operating Officer of Vericel Corp, was granted stock options for 52,500 shares and 21,000 restricted stock units (RSUs).
  • The stock options have an exercise price of $54.31 and vest in equal quarterly installments over four years, starting February 20, 2025.
  • The RSUs vest in four annual installments, starting on February 20, 2026, and continuing on February 20, 2027, February 20, 2028, and February 20, 2029.
  • Each RSU represents a contingent right to receive one share of Vericel Corporation common stock.
  • Following the transaction, Halpin directly owns 52,500 stock options and 21,000 RSUs.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating confidence in the company's future performance. The sentiment is neutral to positive.

Positives

  • The grant of stock options and RSUs to the COO aligns his interests with those of the shareholders.
  • The vesting schedules encourage long-term commitment from the COO.

Industry Context

Stock option and RSU grants are common compensation practices for executives in publicly traded companies, particularly in the biotech and pharmaceutical industries, to incentivize performance and align management's interests with shareholder value.

Comparison to Industry Standards

  • Comparing Vericel's executive compensation structure to similar biotech companies like CRISPR Therapeutics or bluebird bio, stock options and RSU grants are standard practice.
  • The vesting schedules are also typical, with quarterly or annual vesting over a 3-4 year period being common.
  • The specific number of options and RSUs granted would need to be benchmarked against companies of similar size and market capitalization to determine if it is above or below industry averages.

Stakeholder Impact

  • The grant of equity to the COO can positively impact shareholders by aligning management's interests with long-term value creation.
  • Employees may view this as a positive sign of the company's commitment to its leadership.

Key Dates

DateDescription
02/20/2025Date of the transaction: grant of stock options and RSUs.
02/20/2025Stock options vesting start date.
02/20/2026First vesting date for RSUs.
02/20/2027Second vesting date for RSUs.
02/20/2028Third vesting date for RSUs.
02/20/2029Final vesting date for RSUs.
02/20/2035Expiration date for the stock options.
02/24/2025Date of Form 4 filing.

Keywords

Vericel Corp, Michael Halpin, Stock Options, Restricted Stock Units, RSU, Officer, Form 4, Beneficial Ownership

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.